Evidence map›Paper›PMID 23843511›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2013

Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions.

Elisabete Augusto, Marco Matos, Jean Sévigny, Ali El-Tayeb, Margaret S Bynoe, Christa E Müller, Rodrigo A Cunha, Jiang-Fan Chen

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 150 citations in OpenAlex.

  1. Dual CD73/AFrontiers in pharmacology · 2026
    Article
  2. Review
  3. Article
  4. Mitochondrial Localization and Function of Adenosine Receptors.International journal of biological sciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Adenosine and adenosine receptors in metabolic imbalance-related neurological issues.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2024
    Review
  10. Article
  11. Feedback facilitation by adenosine APurinergic signalling · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Adenosine ABiomolecules · 2023
    Article
  16. Striatopallidal adenosine ANeuropharmacology · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 5 countries.

Elisabete AugustoDepartment of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.
Marco Matos
Jean Sévigny
Ali El-Tayeb
Margaret S Bynoe
Christa E Müller
Rodrigo A Cunha
Jiang-Fan Chen
Boston University · USUniversity of Bonn · DECentre hospitalier universitaire de Québec · CACornell University · USInstitut des Sciences Cognitives Marc Jeannerod · FR

Funding

Epigenetic Markers in Huntington's disease BrainR01NS073947 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MYERS, RICHARD H · 2011 to 2015
$3.1M
NOVEL BENEFIT OF A2A RECEPTOR INACTIVATION IN PD MODELSR01NS041083 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JIANG-FAN · 2001 to 2013
$3.1M
NINDS NIH HHS NS041083-11NINDS NIH HHS NS073947NINDS NIH HHS R01 NS041083NINDS NIH HHS R01 NS073947
6 · The paper itself

Abstract

Adenosine is a neuromodulator acting through inhibitory A1 receptors (A1Rs) and facilitatory A2ARs, which have similar affinities for adenosine. It has been shown that the activity of intracellular adenosine kinase preferentially controls the activation of A1Rs, but the source of the adenosine activating A2ARs is unknown. We now show that ecto-5'-nucleotidase (CD73), the major enzyme able to convert extracellular AMP into adenosine, colocalizes with A2ARs in the basal ganglia. In addition to astrocytes, striatal CD73 is prominently localized to postsynaptic sites. Notably, CD73 coimmunoprecipitated with A2ARs and proximity ligation assays confirmed the close proximity of CD73 and A2ARs in the striatum. Accordingly, the cAMP formation in synaptosomes as well as the hypolocomotion induced by a novel A2AR prodrug that requires CD73 metabolization to activate A2ARs were observed in wild-type mice, but not in CD73 knock-out (KO) mice or A2AR KO mice. Moreover, CD73 KO mice displayed increased working memory performance and a blunted amphetamine-induced sensitization, mimicking the phenotype of global or forebrain-A2AR KO mice, as well as upon pharmacological A2AR blockade. These results show that CD73-mediated formation of extracellular adenosine is responsible for the activation of striatal A2AR function. This study points to CD73 as a new target that can fine-tune A2AR activity, and a novel therapeutic target to manipulate A2AR-mediated control of striatal function and neurodegeneration.

Indexed as

5'-NucleotidaseAdenosineAdenosine A2 Receptor AntagonistsAnimalsCorpus StriatumFemaleMaleMiceMice, Inbred C57BLMice, KnockoutPyrimidinesReceptor, Adenosine A2ATriazoles5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine5'-NucleotidaseAdenosineAdenosine A2 Receptor AntagonistsPyrimidinesReceptor, Adenosine A2ATriazoles

Identifiers

PMID23843511
PMCPMC3724543
OpenAlexW2109244578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.